Keyword Analysis & Research: soligenix


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
soligenix0.860.85826829

Keyword Research: People who searched soligenix also searched

Keyword CPC PCC Volume Score
soligenix1.990.489263
soligenix stock0.990.468286
soligenix stock price1.31380564
soligenix news0.810.5490398
soligenix aktie0.090.6114584
soligenix website1.210.7570463
soligenix stock forecast0.840.7866342
soligenix stocktwits1.311616856
soligenix fda1.490.216248
soligenix cannabis0.520.846361
soligenix uk1.880.3862148
soligenix ipo0.20.3678654
soligenix dex0.620.8716917

Search Results related to soligenix on Search Engine

  • Late-Stage Biopharmaceutical Company | Soligenix

    soligenix.com

    https://www.soligenix.com/

    WEBApr 11, 2024 · Rising to the challenges of rare disease treatment. Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

    DA: 83 PA: 34 MOZ Rank: 31

  • Soligenix, Inc. (SNGX) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/SNGX

    WEBFind the latest Soligenix, Inc. (SNGX) stock quote, history, news and other vital information to help you with your stock trading and investing.

    DA: 41 PA: 34 MOZ Rank: 44

  • Rare Disease Pipeline and Programs | Soligenix

    soligenix.com

    https://www.soligenix.com/pipeline-programs/

    WEBSoligenix pipeline programs focus on the development of specialized biotherapeutics and public health solutions for rare and orphan diseases. Learn more.

    DA: 52 PA: 8 MOZ Rank: 40

  • About Soligenix, a late-stage biopharmaceutical company

    soligenix.com

    https://www.soligenix.com/about/

    WEBSoligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as ...

    DA: 59 PA: 90 MOZ Rank: 78

  • Soligenix Announces Publication Demonstrating Complete …

    yahoo.com

    https://finance.yahoo.com/news/soligenix-announces-publication-demonstrating-complete-123000193.html

    WEBJan 2, 2024 · Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses. PRINCETON, N.J., Jan. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX ...

    DA: 51 PA: 8 MOZ Rank: 4


  • Soligenix Announces Agreement on the Design of a Second …

    yahoo.com

    https://finance.yahoo.com/news/soligenix-announces-agreement-design-second-113000709.html

    WEBApr 3, 2024 · Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

    DA: 39 PA: 91 MOZ Rank: 84

  • Our Focus on Unmet Medical Needs | Soligenix

    soligenix.com

    https://www.soligenix.com/our-focus/

    WEBLearn more about our scientific advisors. Our pipeline focuses on orphan and unmet medical needs across a range of indications. Soligenix, a late-stage biopharmaceutical company focused on developing commercializing …

    DA: 55 PA: 43 MOZ Rank: 42

  • Our Expertise in Clinical Trials | Soligenix

    soligenix.com

    https://www.soligenix.com/clinical-trials/

    WEBSoligenix has specialized clinical trial expertise. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

    DA: 47 PA: 37 MOZ Rank: 85

  • Soligenix Announces Top-line Results of the Phase 2a Study of …

    soligenix.com

    https://ir.soligenix.com/2024-01-04-Soligenix-Announces-Top-line-Results-of-the-Phase-2a-Study-of-SGX302-Synthetic-Hypericin-in-Patients-with-Mild-to-Moderate-Psoriasis

    WEBPRINCETON, N.J., Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its ongoing Phase 2a trial …

    DA: 52 PA: 47 MOZ Rank: 52

  • Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial …

    soligenix.com

    https://ir.soligenix.com/2023-11-30-Soligenix-Receives-FDA-IND-Clearance-for-Phase-2-Clinical-Trial-of-Dusquetide-in-the-Treatment-of-Aphthous-Ulcers-in-Behcets-Disease

    WEBPRINCETON, N.J., Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has …

    DA: 55 PA: 81 MOZ Rank: 7